Related Experiment Videos
[Immunologic behavior of meningococcal vaccines]
1Seção de Imunologia do Instituto Adolfo Lutz, São Paulo, Brasil.
Revista De Saude Publica
|August 1, 1997
Summary
Meningococcal vaccines target A and C strains effectively, but a universal vaccine for serogroup B remains elusive due to immune evasion. Research focuses on developing new meningococcal B vaccines for comprehensive protection.
Area of Science:
- Immunology
- Vaccinology
- Microbiology
Context:
- Meningococcal disease poses a global health challenge, necessitating effective prevention strategies.
- Existing polysaccharide vaccines (A and C) show efficacy but vary by age group.
- A significant gap exists in preventing serogroup B meningococcal disease.
Purpose:
- To review the development and immunological behavior of meningococcal vaccines.
- To explore strategies for creating an immunogenic and safe vaccine against meningococcal B.
- To assess progress towards a vaccine offering broad protection against all meningococci.
Summary:
- Meningococcal vaccines are crucial for disease control, with polysaccharide A and C vaccines demonstrating partial success.
- The meningococcal B capsular polysaccharide is poorly immunogenic due to molecular mimicry, hindering vaccine development.
- Current research focuses on carrier protein conjugates to elicit a robust immune response against serogroup B for all age groups.
Impact:
- Advances in meningococcal vaccine development aim to provide comprehensive protection against invasive meningococcal disease.
- Successful development of a meningococcal B vaccine would address a critical unmet medical need.
- Improved vaccines are essential for controlling outbreaks and reducing the global burden of meningococcal disease.